Press release Archives - PhotoPharmics https://photopharmics.com/category/press-release/ A New Therapy for Neurodegenerative Diseases Thu, 28 Aug 2025 14:38:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.2 https://photopharmics.com/wp-content/uploads/2017/04/cropped-icon-32x32.png Press release Archives - PhotoPharmics https://photopharmics.com/category/press-release/ 32 32 PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy https://photopharmics.com/photopharmics-forms-commercial-advisory-board-to-guide-market-launch-of-breakthrough-parkinsons-therapy/ Thu, 28 Aug 2025 14:00:43 +0000 https://photopharmics.com/?p=6253 The post PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy appeared first on PhotoPharmics.

]]> PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies https://photopharmics.com/photopharmics-expands-enrollment-beyond-300-in-groundbreaking-trial-to-show-improvement-beyond-current-therapies/ Mon, 11 Aug 2025 14:00:28 +0000 https://photopharmics.com/?p=6227 New clinical sites open in Illinois, Florida, and Arizona; trial remains open to participants across 19 states. PhotoPharmics, the leader in specialized phototherapy for neurodegenerative diseases, announced today that it is expanding study access to states that have recently added site investigators. Some of these states, like Illinois, Florida, and Arizona, are critical because of […]

The post PhotoPharmics Expands Enrollment Beyond 300 in Groundbreaking Trial to Show Improvement Beyond Current Therapies appeared first on PhotoPharmics.

]]> PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider https://photopharmics.com/photopharmics-strengthens-executive-team-with-appointments-of-samantha-john-and-greg-schneider/ Wed, 21 May 2025 16:00:29 +0000 https://photopharmics.com/?p=6136 The post PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider appeared first on PhotoPharmics.

]]> PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device https://photopharmics.com/photopharmics-closes-oversubscribed-6-million-series-b-extension-to-advance-fda-breakthrough-parkinsons-device/ Fri, 18 Apr 2025 15:43:26 +0000 https://photopharmics.com/?p=6086 Original Press Release Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants SALT LAKE CITY – PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its oversubscribed $6 million Series B extension. The round was led by Kickstart Fund with participation from current and […]

The post PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device appeared first on PhotoPharmics.

]]> PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial https://photopharmics.com/photopharmics-reaches-200-participants-in-landmark-light-for-pd-clinical-trial/ Mon, 07 Apr 2025 21:13:21 +0000 https://photopharmics.com/?p=5898 Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]

The post PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial appeared first on PhotoPharmics.

]]> PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board https://photopharmics.com/photopharmics-announces-leadership-transition-in-clinical-scientific-advisory-board/ Fri, 31 Jan 2025 17:00:00 +0000 https://photopharmics.com/?p=5846 PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced the appointment of Robert A. Hauser, MD, MBA, as the new Chairman of its Clinical & Scientific Advisory Board (CSAB). Dr. Hauser assumes this leadership role following the recent passing of Warren Olanow, MD, FRCPC, a visionary in the field of Parkinson’s disease research […]

The post PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board appeared first on PhotoPharmics.

]]> PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting https://photopharmics.com/photopharmics-to-present-patient-interest-findings-from-groundbreaking-remote-parkinsons-trial-at-psg-annual-meeting/ Thu, 05 Dec 2024 16:00:25 +0000 https://photopharmics.com/?p=5769 Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

The post PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting appeared first on PhotoPharmics.

]]> PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s https://photopharmics.com/photopharmics-announces-first-subject-completes-fda-pivotal-clinical-trial-for-the-celeste-device-in-parkinsons/ Sun, 29 Sep 2024 12:18:51 +0000 https://photopharmics.com/?p=5713 PhotoPharmics, a leader in non-invasive phototherapy for neurological disorders, has reached a significant milestone in its ongoing FDA pivotal “Light for PD” trial for the Celeste therapeutic device. The first subject has successfully completed the full 6-month treatment course and clinical visits, marking an important step towards the successful completion of the trial and future FDA authorization of Celeste in treating Parkinson’s disease (PD).

The post PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinson’s appeared first on PhotoPharmics.

]]> PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board https://photopharmics.com/photopharmics-welcomes-three-renowned-experts-to-its-clinical-scientific-advisory-board/ Thu, 12 Sep 2024 14:58:25 +0000 https://photopharmics.com/?p=5672 PhotoPharmics, an innovator in light-based therapies for neurodegenerative diseases, proudly announces the appointment of three eminent experts to its Clinical & Scientific Advisory Board (CSAB). The new members—Dr. Charles H. Adler, Dr. George Brainard, and Dr. Robert A. Hauser—bring unparalleled expertise to the advisory board, reinforcing PhotoPharmics' mission to pioneer groundbreaking treatments for Parkinson’s disease and other neurodegenerative disorders.

The post PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board appeared first on PhotoPharmics.

]]> PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial https://photopharmics.com/photopharmics-enrolls-first-100-participants-in-groundbreaking-parkinsons-disease-trial/ Thu, 08 Aug 2024 16:00:10 +0000 https://photopharmics.com/?p=5661 PhotoPharmics, a leader in neurodegenerative disease phototherapy, today announced the enrollment of the first 100 subjects in its Light for PD clinical trial. This marks a significant milestone in evaluating Celeste, the company’s FDA Breakthrough light therapy device for Parkinson's disease (PD). Organizers are on track to enroll 300 subjects—interested individuals with PD may find details at lightforpd.com.

The Light for PD trial is a randomized, double-blind, placebo-controlled study that aims to demonstrate safety and significant improvement in motor and non-motor symptoms beyond current medical care in PD.  Parkinson’s disease happens when the brain can no longer regulate essential signaling for movement and other function. Recent discoveries implicate the eyes as part of this signaling process. Celeste passively delivers specific wavelengths of light aimed to restore retinal signaling, improving function and quality of life for those living with PD.

The post PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson’s Disease Trial appeared first on PhotoPharmics.

]]>